22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
18:42 , Mar 8, 2019 |  BC Extra  |  Company News

TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer....
17:36 , Mar 8, 2019 |  BC Week In Review  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions on March 1, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first...
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
22:10 , Mar 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions Friday, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first approved antidote...
20:10 , Mar 1, 2019 |  BC Week In Review  |  Company News

Clovis gains on 4Q increase in Rubraca sales

Clovis Oncology Inc. (NASDAQ:CLVS) reported $30.4 million in 4Q18 revenue, all from U.S. sales of Rubraca rucaparib, up 78% from $17 million in 4Q17 and beating the consensus estimate of $27 million. For the year,...
02:44 , Feb 28, 2019 |  BC Week In Review  |  Clinical News

Lynparza notches first in POLO trial of pancreatic cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) announced the first positive data for a targeted agent in a molecularly defined subgroup of patients with metastatic pancreatic cancer. On Feb. 26, the...
17:50 , Feb 26, 2019 |  BC Extra  |  Clinical News

Lynparza notches first in POLO trial of pancreatic cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) announced the first positive data for a targeted agent in a molecularly defined subgroup of patients with metastatic pancreatic cancer. On Tuesday, the companies...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
22:45 , Feb 14, 2019 |  BC Extra  |  Company News

MedImmune vanishes as AZ restructures, returns to growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) recorded its first year of product sales growth since 2009 and unveiled a new R&D structure in its 2018 earnings report Thursday. With the restructuring, AZ will drop the MedImmune unit...